FrancophonIA/ELRC3.0 huggingface dataset:
English: • The Committee noted that the pre-existence of some of the indicated diseases to be treated with bufexamac may constitute risk factors for bufexamac sensitisation and serious hypersensitivity reactions.
Slovenian: • Odbor je ugotovil, da predhodni obstoj nekaterih indiciranih bolezni, ki jih je treba zdraviti z bufeksamakom, lahko pomeni dejavnike tveganja za preobčutljivost na bufeksamak in hude preobčutljivostne reakcije.
English: • acute und chronic anal inflammatory symptoms of skin,
Slovenian: • akutni in kronični simptomi analnega kožnega vnetja,
English: • inflammatory conditions of anus and rectum,
Slovenian: • vnetna stanja anusa in rektuma,
English: • eczema,
Slovenian: • ekcem,
English: In addition the CHMP notes that the pre-existence of some of the indicated diseases to be treated with bufexamac constitute risk factors for bufexamac sensitisation.
Slovenian: Poleg tega je CHMP ugotovil, da predhodni obstoj nekaterih indiciranih bolezni, ki jih je treba zdraviti z bufeksamakom, pomeni dejavnike tveganja za preobčutljivost na bufeksamak.
English: Risk minimisation measures such as changes to the Product Information (contraindications and strengthened warnings) and/or restriction of availability were proposed by the MAHs in their response document to the List of Questions adopted by the Committee.
Slovenian: Imetniki dovoljenja za promet z zdravilom so v svojem dokumentu z odgovori na seznam vprašanj, ki ga je sprejel Odbor, predlagali ukrepe za zmanjšanje tveganja, kot so spremembe podatkov o zdravilu (kontraindikacije in okrepljena opozorila) in/ali omejitev razpoložljivosti.
English: 250mg Bufexamac, +10mg Lidocaine suppository
Slovenian: 250mg Bufexamac, +10mg Lidocaine
English: Bufexamac is used as a non-steroidal antiphlogistic substance for topical treatment of several dermatological and proctological diseases.
Slovenian: Bufeksamak se uporablja kot nesteroidna antiflogistična snov za topično zdravljenje različnih dermatoloških in proktoloških bolezni.
English: Rectal use and Cutaneous use
Slovenian: Rektalna uporaba and Dermalna uporaba
English: Bufexamac is used as a non-steroidal antiphlogistic substance for topical treatment of dermatological and proctological diseases.
Slovenian: Bufeksamak se uporablja kot nesteroidna antiflogistična snov za topično zdravljenje dermatoloških in proktoloških bolezni.
English: Numerous case reports of allergic contact-dermatitis after application of bufexamac, partly serious and generalised or requiring hospitalisation, have been collected in ADR databases.
Slovenian: V zbirkah podatkov o neželenih učinkih so zbrana številna poročila o posameznih primerih alergijskega kontaktnega dermatitisa po uporabi bufeksamaka, ki so delno hudi in generalizirani oziroma zahtevajo hospitalizacijo.
English: Rectal ointment
Slovenian: Rektalna uporaba
English: Bulgaria Stada Arzneimittel AG Stadastrasse 2-1
Slovenian: Bolgarija Stada Arzneimittel AG Stadastrasse 2-1
English: 250 mg suppository
Slovenian: 250 mg
English: Cutaneous emulsion
Slovenian: Dermalna emulzija
English: 50 mg rectal cream Rectal use
Slovenian: Rektalna krema Rektalna uporaba
English: Bulgaria Stada Arzneimittel AG, Stadastrasse 2-18
Slovenian: Bolgarija Stada Arzneimittel AG, Stadastrasse 2-18
English: • acute and chronic anal eczema,
Slovenian: • akutni in kronični analni ekcem,
English: Slovakia STADA Arzneimittel AG Stadastrasse 2 - 18
Slovenian: Slovaška STADA Arzneimittel AG Stadastrasse 2 - 18
English: MASTU S FORTE Bufexamac 250 mg, Bismuth subgallate 100 mg, Titanium dioxide 100 mg, Lidocaine hydrochloride 10 mg suppository
Slovenian: MASTU S FORTE Bufexamac 250 mg, Bismuth subgallate 100 mg, Titanium dioxide 100 mg, Lidocaine hydrochloride 10 mg
English: Marketing Authorisation Holder (Invented) Name Strength
Slovenian: Izmišljeno ime Ime
English: Romania STADA ARZNEIMITTEL AG Stadastrasse 2-18
Slovenian: Romunija STADA ARZNEIMITTEL AG Stadastrasse 2-18
English: Hungary Stada Arzneimittel AG Stadastrasse 2-18
Slovenian: Madžarska Stada Arzneimittel AG Stadastrasse 2-18
English: Bufexamac 50 mg/g, Bismuth subgallate 50 mg/g, Titanium dioxide 50 mg/g, Lidocaine hydrochloride 5 mg/g rectal ointment
Slovenian: Bufexamac 50 mg/g, Bismuth subgallate 50 mg/g, Titanium dioxide 50 mg/g, Lidocaine hydrochloride 5 mg/g
English: The patient usually receives 3 infusions within one week.
Slovenian: Bolnik običajno prejme tri infuzije v enem tednu.
English: These side effects can be serious in more than 1 in 10 people.
Slovenian: Ti neželeni učinki so lahko resni pri več kot 1 od 10 bolnikov.
English: If the cancer responds to initial treatment, the patient may receive further ‘consolidation' treatment to keep the cancer from coming back.
Slovenian: Če se rak odzove na začetno zdravljenje, lahko bolnik prejme nadaljnje „konsolidacijsko“ zdravljenje, ki preprečuje, da bi se rak ponovil.
English: The patient is also given medicines to help prevent reactions such as reddening of the skin, chills and fever.
Slovenian: Bolnik prejme tudi zdravila za preprečevanje reakcij, kot so pordela koža, mrzlica in vročina.
English: What measures are being taken to ensure the safe and effective use of Mylotarg?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Mylotarg?
English: The European Medicines Agency decided that Mylotarg's benefits are greater than its risks and it can be authorised for use in the EU.
Slovenian: Evropska agencija za zdravila je zaključila, da so koristi zdravila Mylotarg večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
English: Mylotarg infusions must be given in a place (such as a hospital) where the patient can be resuscitated if there are severe reactions.
Slovenian: Infuzije zdravila Mylotarg je treba dajati na kraju (npr. v bolnišnici), kjer je bolnika v primeru hudih reakcij mogoče oživljati.
English: Further information on Mylotarg can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Nadaljnje informacije za zdravilo Mylotarg so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: As for all medicines, data on the use of Mylotarg are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Mylotarg stalno spremljajo.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Mylotarg have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Mylotarg upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: It is not used for a type of AML called acute promyelocytic leukaemia (APL).
Slovenian: Ne uporablja se za vrsto AML, imenovano akutna promielocitna levkemija (APL).
English: For more information about using Mylotarg, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Mylotarg glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: Side effects reported with Mylotarg are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Mylotarg, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: Other information about Mylotarg
Slovenian: Druge informacije o zdravilu Mylotarg
English: Mylotarg is given as an infusion into a vein lasting 2 hours.
Slovenian: Zdravilo Mylotarg se daje kot infuzija v veno, ki traja 2 uri.
English: Although some side effects with Mylotarg can be serious, they were considered acceptable in light of the severity of the patients' condition.
Slovenian: Čeprav so lahko nekateri neželeni učinki zdravila Mylotarg resni, so bili glede na resnost bolnikove bolezni ocenjeni kot sprejemljivi.
English: The patient will also be given two other medicines: daunorubicin and cytarabine.
Slovenian: Bolnik prejme tudi dve drugi zdravili: daunorubicin in citarabin.
English: An overview of Mylotarg and why it is authorised in the EU
Slovenian: Pregled zdravila Mylotarg in zakaj je odobreno v EU
English: Why is Mylotarg authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Mylotarg odobreno v EU?
English: What benefits of Mylotarg have been shown in studies?
Slovenian: Kakšne koristi zdravila Mylotarg so se pokazale v študijah?
English: What is Mylotarg and what is it used for?
Slovenian: Kaj je zdravilo Mylotarg in za kaj se uporablja?
English: AML is rare, and Mylotarg was designated an ‘orphan medicine' (a medicine used in rare diseases) on 18 October 2000.
Slovenian: AML je redka bolezen, zato je bilo zdravilo Mylotarg 18. oktobra 2000 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
English: It is used in combination with daunorubicin and cytarabine (other cancer medicines).
Slovenian: Uporablja se v kombinaciji z daunorubicinom in citarabinom (drugima zdraviloma za zdravljenje raka).
English: The most common side effects with Mylotarg when given in combination with daunorubicin and cytarabine (which may affect more than 3 in 10 people) are bleeding and severe infections.
Slovenian: Najpogostejši neželeni učinki zdravila Mylotarg pri dajanju v kombinaciji z daunorubicinom in citarabinom (ki se lahko pojavijo pri več kot 3 od 10 bolnikov) so krvavitev in hude okužbe.
English: What are the risks associated with Mylotarg?
Slovenian: Kakšna tveganja so povezana z zdravilom Mylotarg?
English: The calicheamicin then breaks up the cells' DNA, eventually killing the cells.
Slovenian: Kaliheamicin razcepi celično DNK, kar uniči celice.
English: Inside the cells, the cytotoxic substance, which is called calicheamicin, is released.
Slovenian: V celicah se citotoksična snov, imenovana kaliheamicin, sprosti.
English: Other serious side effects with the combination therapy are liver disease, including veno-occlusive disease (a liver injury), and tumour lysis syndrome (a complication due to the breakdown of cancer cells).
Slovenian: Druga resna neželena učinka kombiniranega zdravljenja sta bolezen jeter, vključno z venookluzivno boleznijo (poškodba jeter), in sindrom tumorske lize (zaplet zaradi razpada rakavih celic).
English: When the antibody attaches to CD33 on leukaemia cells, the cells absorb the antibody, as well as the cytotoxic substance that it is attached to.
Slovenian: Ko se protitelo veže na CD33 na levkemičnih celicah, te absorbirajo protitelo in nanj vezano citotoksično snov.
English: Mylotarg is used in patients with a protein called CD33 on their cancer cells (which is the case in most patients with AML).
Slovenian: Zdravilo Mylotarg se uporablja pri bolnikih, ki imajo na rakavih celicah beljakovino CD33 (kar velja za večino bolnikov z AML).
English: Mylotarg is a medicine used to treat a blood cancer called acute myeloid leukaemia (AML) in patients aged 15 years and above who are newly diagnosed and have not tried other treatments.
Slovenian: Mylotarg je zdravilo, ki se uporablja za zdravljenje krvnega raka, imenovanega akutna mieloična levkemija (AML), pri bolnikih, starih 15 let in več, z novo postavljeno diagnozo, ki še niso poskusili drugih zdravljenj.
English: A main study in 271 patients with AML has shown that adding Mylotarg to daunorubicin and cytarabine can prolong the time patients live without their cancer coming back by around 8 months.
Slovenian: Glavna študija z 271 bolniki z AML je pokazala, da lahko dodatek zdravila Mylotarg daunorubicinu in citarabinu podaljša čas, ki ga bolniki preživijo brez ponovitve raka, za okoli osem mesecev.
English: The monoclonal antibody part (gemtuzumab) has been designed to attach to CD33.
Slovenian: Monoklonsko protitelo (gemtuzumab) je zasnovano za vezavo na CD33.
English: In patients receiving Mylotarg in combination with daunorubicin and cytarabine, it took an average of 17.3 months until the treatment failed, the cancer came back or the patient died, compared with 9.5 months in patients receiving a combination of only daunorubicin and cytarabine.
Slovenian: Pri bolnikih, ki so prejemali zdravilo Mylotarg v kombinaciji z daunorubicinom in citarabinom, je do prenehanja učinkovitosti zdravljenja, ponovitve raka ali smrti bolnika trajalo povprečno 17,3 meseca, pri bolnikih, ki so prejemali kombinacijo samo daunorubicina in citarabina, pa 9,5 meseca.
English: For the full list of side effects and restrictions with Mylotarg, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Mylotarg glejte navodilo za uporabo.
English: The active substance in Mylotarg, gemtuzumab ozogamicin, consists of two parts: a cytotoxic (cellkilling) substance and a monoclonal antibody (a type of protein).
Slovenian: Učinkovina v zdravilu Mylotarg, gemtuzumab ozogamicin, je sestavljena iz dveh delov: citotoksične (ki uničuje celice) snovi in monoklonskega protitelesa (vrsta beljakovine).
English: Mylotarg contains the active substance gemtuzumab ozogamicin.
Slovenian: Mylotarg vsebuje učinkovino gemtuzumab ozogamicin.
English: Mylotarg, given in combination with daunorubicin and cytarabine, has been shown to prolong the time patients lived before the cancer came back by up to 8 months.
Slovenian: Izkazalo se je, da zdravilo Mylotarg v kombinaciji z daunorubicinom in citarabinom podaljša čas, ki ga bolniki preživijo pred ponovitvijo raka, za do osem mesecev.
English: How is Mylotarg used?
Slovenian: Kako se zdravilo Mylotarg uporablja?
English: How does Mylotarg work?
Slovenian: Kako zdravilo Mylotarg deluje?
English: Mylotarg can only be obtained with a prescription.
Slovenian: Predpisovanje in izdaja zdravila Mylotarg je le na recept.
English: Cardboard box containing either 1 or 6 bottles.
Slovenian: Kartonska škatla vsebuje 1 ali 6 steklenic.
English: Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/ .
Slovenian: Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu/.
English: Do not store above 25 °C.
Slovenian: Ne shranjujte pri temperaturi nad 25°C.
English: For the full list of excipients, see section 6.1.
Slovenian: Za celoten seznam pomožnih, snovi glejte poglavje 6.1.
English: THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE
Slovenian: BESEDILO “SAMO ZA ŽIVALI” IN POGOJI IN OMEJITVE GLEDE OSKRBE IN UPORABE, ČE JE SMISELNO
English: Clear, colourless liquid.
Slovenian: Bistra, brezbarvna tekočina.
English: If these symptoms occur, remove the individual from the source of exposure and seek medical attention.
Slovenian: Če se pojavijo ti simptomi, je treba osebo odstraniti od vira izpostavljenosti in poiskati zdravniško pomoč.
English: Do not use this veterinary medicinal product after the expiry date which is stated on the label.
Slovenian: Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na nalepki.
English: Pharmacotherapeutic group: inhalation anaesthetic, ATCvet code: QN 01AB08
Slovenian: FARMAKOLOŠKE LASTNOSTI Farmakoterapevtska skupina: Inhalacijski anestetik, oznaka ATCvet: QN 01AB08.
English: Sevohale contains no stabiliser and does not affect the calibration or operation of these vaporisers in any way.
Slovenian: Sevohale ne vsebuje nobenega stabilizatorja in nikakor ne vpliva na kalibracijo ali delovanje teh hlapilnikov.
English: 250 ml Type III amber glass bottle with a yellow collar on the neck, sealed with a poly-seal cap, and secured with PET film.
Slovenian: 250-ml Type III rjava steklenica z rumeno ovratnico na vratu, zaprta s poli-tesnilno zaporko in zavarovana s PET folijo.
English: In the dog, sevoflurane may increase intracranial pressure at concentrations of 2.0 MAC and above under normal partial pressures of carbon dioxide (normocapnia), but intracranial pressure has been shown to remain within normal range at sevoflurane concentrations of up to 1.5 MAC if hypocapnia is induced by hyperventilation.
Slovenian: Sevofluran lahko zviša intrakranialni tlak pri koncentracijah 2,0 MAC in več, pri normalnih parcialnih tlakih ogljikovega dioksida (normokapnija), vendar se je pokazalo, da intrakranialni tlak ostane v normalnih mejah pri koncentracijah sevoflurana do 1,5 MAC, če se hipokapnija inducira s hiperventilacijo.
English: D OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
Slovenian: D. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM
English: Limited clinical experience in administering sevoflurane to animals with renal, hepatic and cardiovascular insufficiency suggests that sevoflurane may be safely used in these conditions.
Slovenian: Omejene klinične izkušnje z uporabo sevoflurana pri živalih z ledvično, jetrno in kardiovaskularno insuficienco kažejo, da lahko sevofluran pri teh boleznih varno uporabljamo.
English: In dogs exposed to 4% sevoflurane for 3 hours, mean peak maximum serum fluoride concentrations of 20.0 ± 4.8 µmol/l have been observed after 3 hours of anaesthesia.
Slovenian: Pri psih, izpostavljenih 4-odstotnemu sevofluranu 3 ure dolgo, so opazovali srednji vrh najvišjih serumskih koncentracij fluorida 20,0 ± 4,8 μmol/l po 3 urah anestezije.
English: Date of first authorisation: 21/06/2016
Slovenian: DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum pridobitve dovoljenja za promet: 21/06/2016.
English: 100% v/v sevoflurane
Slovenian: 100 % v/v sevofluran
English: In case of accidental contact with the skin, wash the affected area with abundant water.
Slovenian: V primeru nehotenega stika s kožo sperite prizadeti predel z obilico vode.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION
Slovenian: KAKOVOSTNA IN KOLIČINSKA SESTAVA Zdravilna učinkovina:
English: Sevohale should be administered via a vaporiser specifically calibrated for use with sevoflurane so that the concentration delivered can be accurately controlled.
Slovenian: Sevohale je treba dajati s hlapilnikom, ki je posebej kalibriran za uporabo s sevofluranom, tako da je možno koncentracijo v vdihanem zraku natančno kontrolirati.
English: Sevohale overdose may result in profound respiratory depression.
Slovenian: Preveliko odmerjanje Sevohalea lahko povzroči globoko depresijo dihanja.
English: In dogs, concentrations of sevoflurane below 2.0 MAC result in a small net increase in total liver blood flow.
Slovenian: Pri psih koncentracije sevoflurana pod 2,0 MAC povzročijo majhno neto zvečanje celotnega pretoka krvi skozi jetra.
English: 4.4 Special warnings for each target species
Slovenian: 4.4 Posebna opozorila za vsako ciljno živalsko vrsto Ni posebnih opozoril.
English: Sevoflurane 100% v/v
Slovenian: Sevofluran 100 % v/v.
English: In order to minimise this reaction in rebreathing anaesthetic circuits, Sevohale should not be passed through soda lime or barium hydroxide that has been allowed to dry out.
Slovenian: Da to reakcijo v anestezijskih sistemih za povratno dihanje kar najbolj zmanjšamo, sevoflurana ne smemo speljati skozi zmes kalcijevega hidroksida z natrijevim ali kalijevim hidroksidom ali skozi barijev hidroksid, ki smo ga pustili, da se je posušil.
English: Bottle label
Slovenian: Kartonska škatla
English: EU/2/16/196/001-002
Slovenian: ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/2/16/196/001-002
English: • Care should be taken when dispensing Sevohale, with immediate removal of any spillage.
Slovenian: • Pri pripravi Sevohalea moramo biti previdni, morebitno razlito zdravilo je treba nemudoma odstraniti.
English: Limited data are available on the effects of the highly potent alpha-2agonists (medetomidine, romifidine and dexmedetomidine) as premedication.
Slovenian: O učinkih zelo močnih alfa-2-agonistov (medetomidina, romifidina in deksmedetomidina) kot sredstvih za premedikacijo so na voljo omejeni podatki.
English: Alpha-2-agonists cause bradycardia which may occur when they are used with sevoflurane.
Slovenian: Alfa-2agonisti povzročajo bradikardijo, kadar se uporabljajo s sevofluranom.
English: Anaesthetic regimens that include opioid, alpha-2-agonist, benzodiazepine or phenothiazine premedication will allow the use of lower sevoflurane maintenance concentrations.
Slovenian: Anestetične sheme, ki vključujejo premedikacijo z opioidi, alfa-2-agonisti, benzodiazepini ali fenotiazini, dopuščajo uporabo nižjih vzdrževalnih koncentracij sevoflurana.
English: For induction and maintenance of anaesthesia.
Slovenian: Za uvod v anestezijo in vzdrževanje anestezije.
English: Dose-dependent respiratory depression is commonly observed while using sevoflurane, therefore respiration should be closely monitored during sevoflurane anaesthesia and the inspired concentration of sevoflurane adjusted accordingly.
Slovenian: Od odmerka odvisna depresija dihanja se pogosto opazi pri uporabi sevofluranazato je treba med sevofluransko anestezijo dihanje skrbno spremljati in ustrezno prilagajati koncentracijo sevoflurana v vdihanem zraku.
English: Sevoflurane produces only modest increases in cerebral blood flow and metabolic rate, and has little or no ability to potentiate seizures.
Slovenian: Pre psih sevofluran povzroča le zmerno zvišanje možganskega krvnega pretoka in hitrosti presnove in le malo ali sploh ne krepi napade krčev.
English: To be supplied only on veterinary prescription.
Slovenian: Samo za živali, na veterinarski recept
English: Surgical levels of anaesthesia in the healthy dog may be maintained with inhaled concentrations of 3.3 to 3.6% in the presence of premedication.
Slovenian: Kirurške ravni anestezije pri zdravih psih lahko vzdržujemo z inhaliranimi koncentracijami 3,3 do 3,6 % ob premedikaciji.
English: Sevohale 100% v/v Inhalation vapour, liquid for dogs and cats.
Slovenian: Sevohale 100 % v/v para za inhaliranje, tekočina za pse in mačke.
English: Paddling, retching, salivation, cyanosis, premature ventricular contractions and excessive cardiopulmonary depression have been reported very rarely based on post-authorisation spontaneous reporting experience.
Slovenian: Veslanje s tacami, vzdigovanje, slinjenje, cianoza, prezgodnji prekatni utripi in čezmerna kardiopulmonalna depresija so zelo redki neželeni učinki o katerih so poročali po pridobitvi dovoljenja za promet z zdravilom.
English: Sevoflurane may be used for maintenance anaesthesia following mask induction with sevoflurane or following induction with injectable agents.
Slovenian: Sevofluran lahko uporabljamo za vzdrževalno anestezijo po uvedbi z masko in sevofluranom ali po uvedbi s sredstvi za injiciranje.
English: In dogs the concurrent administration of thiopental, however, may slightly increase sensitivity to adrenaline induced cardiac arrhythmias.
Slovenian: Vendar lahko sočasna uporaba tiopentala pri psih rahlo zveča občutljivost za srčne aritmije, inducirane z adrenalinom.
English: The use of injectable induction agents without premedication has little effect on the concentrations of sevoflurane required for maintenance.
Slovenian: Uporaba sredstev za uvod v anestezijo, ki se injicirajo, brez premedikacije le malo vpliva na koncentracije sevoflurana, ki so potrebne za vzdrževanje.
English: CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
Slovenian: B. POGOJI DOVOLJENJA ZA PROMET Z ZDRAVILOM TER OMEJITVE GLEDE OSKRBE ALI UPORABE
English: DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
Slovenian: ODMEREK ZA POSAMEZNE ŽIVALSKE VRSTE TER POT(I) NAČIN UPORABE IN ZDRAVILA
English: A minimal amount of sevoflurane is required to be dissolved in the blood before the alveolar partial pressure is in equilibrium with the arterial partial pressure because of the low solubility of sevoflurane in blood (blood/gas partition coefficient at 30 °C is 0.63 to 0.69).
Slovenian: Zaradi majhne topnosti sevoflurana v krvi (porazdelitveni koeficient med krvjo in plinom pri 30 °C je 0,63 do 0,69) se mora v krvi raztopiti minimalna količina sevoflurana, preden se alveolarni parcialni tlak uravnovesi z arterijskim parcialnim tlakom.